Singapore fast-tracks approvals for health technology and trials
Singapore plans a priority review track for selected innovative health products, and will cut approval times for lower-risk Phase Three trials in half to 15 days. The move aims to reduce red tape for trials and health technology reviews.
By Standard Topic. AI-generated from the reporting listed under Coverage. Published . Updated .
This story is no longer being updated. It reflects reporting up to .
What happened
Singapore will set up a priority track to assess selected innovative health products, according to Health Minister Ong Ye Kung. The government will also halve approval timelines for selected lower-risk Phase Three clinical trials to 15 days. New health regulator initiatives aim to speed up approvals for innovative health products and clinical trials.
Why it matters
Selected innovative health products and lower-risk clinical trials are set to receive faster regulatory decisions. The changes cut red tape for clinical trials and health technology reviews.
Timeline
- Oct 11, 8:00 PM ET: Singapore announced several moves to accelerate healthcare innovations, including a priority track for selected innovative health products.
- Oct 12, 5:15 AM ET: Health Minister Ong Ye Kung said the Health Sciences Authority's new regulatory initiatives would speed up approvals for innovative health products and clinical trials.
- Oct 13, 12:07 AM ET: Singapore announced it will halve approval timelines for selected lower-risk Phase Three clinical trials to 15 days.
Coverage
- SG slashes clinical trial red tape, speeds up health tech reviews (healthcareasiamagazine.com)
- Good medical innovations reach patients sooner with good regulation: Ong Ye Kung (The Straits Times)
- Singapore moves to accelerate healthcare innovations in push to be regional clinical research hub (CNA)
More from Health
- Hackensack Meridian Health and Hunterdon Health agree to merge
- Roche signs $15 billion antibody-drug conjugate deal with Hansoh
- Putin's daughter predicts aging breakthroughs within 10 to 20 years
- Cardiologists urged to prescribe exercise for heart patients
- Pennsylvania measles outbreak tops 1,200 as CDC sends investigator
- AstraZeneca enlists Oracle to apply AI in drug trials